Search PubMed⌕ Search

Biomedical subjects

P M Hinkle

Publications and source records attributed to P M Hinkle.

85 records · Page 5Linked to original sources
PubMed1978

Solubilization of pituitary receptors for thyrotropin-releasing hormone.

Receptors for thyrotropin-releasing hormone were solubilized by Triton X-100. Membrane fractions from GH3 pituitary tumor cells were incubated with thyrotropin-releasing hormone in order to saturate specific receptor sites before the addition of detergent. The amount of protein-bound hormone solubilized by Triton X-100 was proportional to the fractional saturation of specific membrane receptors. Increasing detergent:protein ratios from 0.5 to 20 led to a progressive loss of hormone . receptor complex from membrane fractions with a concomitant increase in soluble protein-bound hormone. The soluble hormone . receptor complex was not retained by 0.22 micron filters and remained soluble after ultracentrifugation. Following incubation with high (2.5--10%) concentrations of Triton X-100 and other non-ionic detergents, or following repeated detergent extraction, at least 18% of specifically bound thyrotropin-releasing hormone remained associated with particulate material. Unlike the hormone receptor complex, the free hormone receptor was inactivated by Triton X-100. A 50% loss of binding activity was obtained with 0.01% Triton X-100, corresponding to a detergent:protein ratio of 0.033. The hormone . receptor complex was included in Sepharose 6B and exhibited an apparent Stoke radius of 46 A in buffers containing Triton X-100. The complex aggregated in detergent-free buffers. Soluble hormone receptors were separated from excess detergent and thyrotropin-releasing hormone by chromatography on DEAE-cellulose. Thyrotropin-releasing hormone dissociated from soluble receptors with a half-time of 120 min at 0 degrees C, while the membrane hormone . receptor complex was stable for up to 5 at 0 degrees C.

Cell Membrane↗
PubMed1977

Adenylyl cyclase and cyclic nucleotide phosphodiesterases in GH-Strains of rat pituitary cells.

The properties of adenylyl cyclase and cyclic nucleotide phosphodiesterases from GH-strains of rat pituitary tumor cells have been investigated. Adenylyl cyclase was inhibited by calcium ion and stimulated by fluoride ion, 5'-guanylylimidodiphosphate and by prior treatment of intact releasing hormone (TRH), which stimulates prolactin releasing hormone (TRH), which stimulates prolactin release and synthesis in GH-cells, did not cause a significant stimulation of adenylyl cyclase activity under a wide variety of assay conditions; under the same conditions, [3H]TRH bound to a previously characterized membrane receptor. GH-cells contain phosphodiesterase activity catalyzing the hydrolysis of cAMP which gives nonliner Lineweaver-Burk plots with apparent Km's for cAMP of 1.5 muM and 4mM. TRH did not affect the activity of cyclic nucleotide phosphodiesterase at high or low cAMP concentrations when added to broken cell preparations. Treatment of intact cells with TRH caused no changes in the total adenylyl cyclase and cyclic nucleotide phosphodiesterase activites within the first 2 h of incubation, when stimulation of prolactin release occurs, but did lead to slight decrease in adenylyl cyclase and the apparent low Km phosphodiesterase after 72 h of treatment.

3',5'-Cyclic-AMP Phosphodiesterases↗
PubMed1975

Thyrotropin-releasing hormone regulates the number of its own receptors in the GH3 strain of pituitary cells in culture.

Thyrotropin-releasing hormone (TRH), a hypothalamic tripeptide, binds rapidly and reversibly to specific membrane receptors on GH3 cells, a clonal strain of rat pituitary cells grown in culture. GH3 cells were incubated for 1-72 hr with unlabeled TRH, washed, and then incubated for 1 hr with [3H]TRH. Under these conditions 80% of any bound, unlabeled TRH exchanges with [3H]TRH in the medium, and the amount of radioactivity bound to the cells gives a measure of the number of TRH receptors. In GH3 cells, the number of available TRH receptors decreased from 92% of control after 1 hr to 35% after 48 or 72 hr of incubation with unlabeled TRH. Binding of [3H]TRH to both intact control and TRH-treated cells was half-maximal at 8 nM [3H]TRH, but the maximum amount of [3H]TRH bound was decreased by 75% in cells previously incubated for 48 hr with unlabeled TRH. Equilibrium binding studies were performed using membrane fractions prepared from control cells and cells previously exposed to TRH for various periods. The dissociation constant of the TRH-receptor complex was the same in all cases, but the maximum amount of TRH bound decreased progressively in membrane fractions from cells incubated with TRH for 1-51 hr. TRH receptors were not found in cytoplasmic fractions of control or TRH-treated cells. The loss of TRH receptors was reversible within 4 days. In the continued presence of the tripeptide the number of receptors remained low for 12 days. After incubation for 2 days with different concentrations of TRH, the number of receptors was decreased to 33% of control at 100-300 nM TRH, and half of this decrease occurred at about 1 nM TRH; half-maximal biological responses occur at 2 nM TRH. The biologically active Ntau-methylhistidyl derivative of TRH also effected a loss of receptors, while three inactive analogs of TRH did not cause reductions in the number of TRH receptors. In cultures incubated for 40 hr with cycloheximide, protein synthesis was inhibited by 85%, but the number of TRH receptors was 76% of control suggesting that the receptor has a long half-life. When GH3 cells were incubated with cycloheximide plus TRH, the number of TRH receptors decreased by only 23% as compared to a decrease of 73% in cells incubated with TRH alone, suggesting that receptor loss is partially dependent on active protein synthesis. We conclude that in GH3 cells TRH regulates the number of its own receptors.

Binding Sites↗
PubMed1975

Degradation of thyrotropin-releasing hormone by the GH3 strain of pituitary cells in culture.

Thyrotropin-releasing hormone (TRH), pGlu-His-ProNH2, binds within 1 h to specific receptors on the GH3 strain of pituitary cells. When GH3 cells were incubated for 2 days with 3 nM [2,3-3H-Pro]TRH, an increasing fraction of the total cellular radioactivity (7% after 1 h, 81% after 43 h) was associated covalently with proteins as determined by dialysis, acid precipitation, and gel filtration; this fraction corresponded to label which could not be displaced from intact GH3 cells by the addition of excess unlabeled TRH. R5 and GH12C1 cells, strains which lack TRH receptors, accumulated 16 or 23%, respectively, as much label from [2,3-3H-Pro]TRH as did GH3 cells in 24 h. After 24 h of incubation with [2,3-3H-Pro]TRH and [14C-His]TRH, the ratio of 14C/3H in GH3 cells was the same as in the culture medium, indicating that the intact tripeptide was taken up by the cells. After 24-48 h of incubation with [2,3-3H-Pro]TRH, GH3 proteins appeared to be labeled randomly as surmised by fractionation on Sephadex G-100, DEAE cellulose, Sepharose 4B and sucrose density gradients. In cultures treated with cycloheximide (10 mug/ml) or proline (6.3 mM) the initial binding of [2,3-3H-Pro]TRH to receptors, measured after 1 h, was 97% or 102% of control. However, the incorporation of label from [2,3-3H-Pro]TRH into an acid-precipitable product after 22 h was inhibited by 81 and 74% by cycloheximide (1 mug/ml) and proline (2.5 mM). Formation of [2,3-3H] proline from [2,3-?3H-Pro] TRH was demonstrated by thin layer chromatography; the percentage of non-protein radioactivity with an Rf of proline increased from 20 to 80% in GH3 cells incubated 1 or 24 h with [2,3-3H-Pro]TRH. We conclude that after binding to receptors on GH3 cells, TRH is slowly metabolized to its constituent amino acids, and the products [2,3-3H]proline or [14C]histidine are incorporated into newly synthesized proteins.

Biological Transport↗
PubMedDate not supplied

Flavopiridol induces apoptosis and caspase-3 activation of a newly characterized Burkitt's lymphoma cell line containing mutant p53 genes.

Burkitt's lymphoma cell lines have been important in vitro models for studying the pathogenesis of Burkitt's lymphoma (BL) and for exploring new treatment strategies. A new EBV(-) Burkitt's lymphoma cell line (GA-10) was established from a patient with a clinically aggressive, chemorefractory BL and characterized. Although functional p-glycoprotein could not be demonstrated by dye-efflux assays, both p53 genes were mutated in the GA-10 cells, perhaps contributing to the resistant phenotype of the original neoplasm. Two properties of BL cells which may be useful targets for novel cytotoxic therapeutics are their surface expression of CD77, the receptor for Shiga toxin (Stx), and their high rate of proliferation. Expression of CD77 on the GA-10 cells was heterogeneous in that certain subclones expressed high levels of CD77 and correspondingly exhibited strong growth inhibition by Stx while others showed low levels of CD77 expression and weak Stx-induced growth inhibition. Flavopiridol, a potent inhibitor of cell cycle progression through G1 and G2, induced cytotoxicity of the GA-10 cells with an LC(50) of approximately 40 nM vs 70 nM for HL-60 cells (P < 0.05). The concentrations of flavopiridol at which only 10% of the cells were viable (LC(10)) were approximately 280 nM for the GA-10 cells and 520 nM for the HL-60 cells (P < 0.05). Dose-related induction of apoptosis in response to flavopiridol was demonstrated in the GA-10 cells by morphology, TUNEL assay, and activation of caspase-3. Flavopiridol was also cytotoxic to seven other BL cell lines tested. These data suggest that flavopiridol may have therapeutic value in the treatment of Burkitt's lymphoma.

ATP Binding Cassette Transporter, Subfamily B, Mem↗